A real‐world prospective observational study of eptinezumab in Asian patients with migraine.

Objective: To evaluate the real‐world effectiveness of eptinezumab for migraine prevention in Asian patients. Background: Eptinezumab is a monoclonal antibody that targets calcitonin gene‐related peptide (CGRP), a potent vasodilator with an important role in migraine pathophysiology. Although there is robust clinical evidence from pivotal Phase 3 placebo‐controlled trials of the efficacy of eptinezumab for migraine prevention, there are limited data on the real‐world effectiveness of eptinezumab in Asian patient cohorts. Methods: This was a non‐interventional, prospective, multisite cohort study of adults with migraine (International Classification of Headache Disorders, 3rd edition criteria) in Singapore who were prescribed eptinezumab (100 mg at baseline and Month 3, administered intravenously) and were followed until Month 6. The primary endpoint was change from baseline in monthly migraine days (MMDs) at Month 3 and Month 6. Secondary endpoints were ≥30% and ≥50% responder rates, and change from baseline in the Headache Impact Test‐6 (HIT‐6), Migraine Disability Assessment (MIDAS), Migraine‐Specific Quality of Life (MSQ), patient‐identified most bothersome symptom (PI‐MBS), acute medication use at Month 3 and Month 6, and safety. Results: Enrolled patients (completed = 29/30) had on average 3.4 (SD 2.9) previous preventive treatments; 29/30 of the patients had trialed at least one previous preventive treatment without benefit. Most had previously trialed oral preventives (87%, 26/30) and anti‐CGRP (70%, 21/30). Relative to baseline, mean MMDs decreased by 4.3 days (95% CI 2.1–6.4; p < 0.001) at Month 3 and 4.9 days (95% CI 2.1–7.7; p < 0.001) at Month 6. At Month 3 and Month 6, 14/30 (47%) and 15/29 (52%) of the patients were ≥30% responders, and 6/30 (20%) and 8/29 (28%) patients were ≥50% responders, respectively. The number of patients with severe life impairment based on the HIT‐6 score (total score 60–78) decreased from 24/30 (80%) at baseline to 19/30 (63%) at Month 3 and 19/29 (66%) at Month 6. The mean MIDAS score decreased by 24.6 points (95% CI 2.82–46.38; p = 0.028) at Month 6, and the mean MSQ score increased by 12.2 points (95% CI 5.18–19.20; p = 0.001) at Month 3 and 13.6 points (95% CI 4.58–22.66; p = 0.004) at Month 6. Most patients reported improvement in the PI‐MBS at Month 3 (73%, 22/30) and Month 6 (55%, 16/29). Acute medication use for headache relief decreased by 3.3 days/month (95% CI 1.0–5.6; p = 0.007) at Month 3 and 4.7 days/month (95% CI 1.7–7.7; p = 0.003) at Month 6. Treatment‐emergent adverse events (TEAEs) were reported in 16/30 (54%) patients, mostly mild/moderate in severity. No serious TEAEs led to treatment discontinuation. Conclusion: Quarterly eptinezumab administration was effective and well‐tolerated in Asian patients with chronic migraine. Plain Language Summary: Numerous studies have shown that eptinezumab is effective for migraine prevention, but there have been limited studies in Asian patients. In this six‐month real‐world study of eptinezumab treatment in 30 Asian patients with chronic migraine (CM), patients were treated with eptinezumab (one dose each at Months 1 and 3) and they reported fewer migraine days per month and improvement in their symptoms, lessened impact of migraine on daily life, and reduced use of medication for acute headache relief after 6 months. These findings support eptinezumab's potential effectiveness as a preventive treatment option in Asian patients with CM. [ABSTRACT FROM AUTHOR]